Saxenda vs Wegovy: Daily Liraglutide vs Weekly Semaglutide
Saxenda and Wegovy are both FDA-approved GLP-1 receptor agonists from Novo Nordisk engineered specifically for chronic weight management. The primary difference is molecular half-life: Saxenda uses Liraglutide, requiring daily administration, whereas Wegovy uses Semaglutide with an extended 7-day duration. While Wegovy produces greater overall weight reduction in clinical trials, patients prone to persistent gastrointestinal upset often prefer Saxenda because any adverse effects dissipate rapidly if a dose is delayed.
Feature-by-Feature Comparison
Saxenda
Wegovy
| Feature / Capability | Saxenda | Wegovy |
|---|---|---|
| Active Molecule | Liraglutide (GLP-1 agonist) | Semaglutide (GLP-1 agonist) |
| Dosing Schedule | Once daily subcutaneous injection | Once weekly subcutaneous injection |
| Average Weight Loss | 8% to 10% total body weight | 15% to 17% total body weight |
| Dose Flexibility | High (Daily dose can be adjusted for side effects) | Fixed weekly titration steps |
| Half-Life | 13 hours | 7 days (168 hours) |
| Food Noise Control | Steady daily suppression | Continuous long-acting suppression |
| Starting Price | $220.00 – $560.00 | $195.00 – $460.00 |
| View Saxenda | View Wegovy |
The Final Verdict
Wegovy offers higher average weight loss (15% vs 9%) and the convenience of a once-weekly injection. However, Saxenda's daily administration gives patients far greater control over nausea, allowing flexible micro-adjustments that prevent severe gastrointestinal intolerance.
Medical Disclaimer
This comparison is for informational purposes only and does not constitute medical advice. The accuracy of pricing and features may change over time. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.
Last updated: September 2026